Back

The GLP1RA Semaglutide exerts significant cardioprotective properties against anthracycline+/-trastuzumab induced cardiotoxicity: biochemical evidences

19 May 2025 (10:00 - 10:45)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology - diagnostic and therapeutic advances Cardio-Oncology HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Nicola Maurea

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)

5 More presentations in this session

Presentation thumbnail
GLP1-RA associated with PCSK9i as new therapy of anthracycline-induced cardiotoxicity under exposure to Ox-LDL: biochemical and preclinical evidences
Doctor N. Maurea (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Use of guideline directed medical therapy and clinical outcomes in cancer patients with de novo heart failure
Doctor Y. Sener (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Detecting global cardiac involvement in breast cancer: the GAVS index
Doctor C. Madaudo (Palermo, IT)
Abstract Slides Video
Presentation thumbnail
Echocardiographic indices of right ventricular function to predict cardiovascular outcomes in asian patients with cardiac amyloidosis
Doctor N. Sari (Jakarta, ID)
Abstract Slides Video
Presentation thumbnail
Bridging cancer and heart health: insights from a cardio-oncology consultation program at a tertiary university hospital
Doctor C. Gregorio (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Cardio-oncology - diagnostic and therapeutic advances

The Event

Event poster

Heart Failure 2025

19 May 2025 10:00 CET
You may be interested in
thumbnail
Congress Presentation
GLP1-RA associated with SGLT2i as new therapy of anthracycline-induced cardiotoxicity under hyperglycemia: biochemical and preclinical evidences
thumbnail
Congress Presentation
GLP1-RA associated with PCSK9i as new therapy of anthracycline-induced cardiotoxicity under exposure to Ox-LDL: biochemical and preclinical evidences
thumbnail
Congress Presentation
NLRP3/IL-1 pathway was reduced by semaglutide and dapagliflozin in association therapy under exposure to anthracyclines in hyperglycemic conditions

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources